MedTrace Logo

The Resistance and Immune Response to Palbociclib in Breast Cancer

NCT03401359 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-17

No results posted yet for this study

Summary

The investigators propose to conduct a biomarker and molecular profiling study in longitudinally paired tumor biopsies and serum from patients with Hormone Receptor positive (HR+) metastatic Breast Cancer (BC) treated with Palbociclib in combination with endocrine therapies.

Conditions

  • Breast Cancer Stage IV

Interventions

GENETIC

tissue biopsy, blood sample

At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2020-10-31
Completion
2022-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401359 on ClinicalTrials.gov